06 agosto 2020
Goldman Sachs says investors are underestimating the chance of a COVID-19 vaccine in 2020
Goldman Sachs says investors are underestimating the chance of a COVID-19 vaccine in 2020, an event that could push the S&P 500 11% higher: "We agree that there is now a good chance that at least one vaccine will be FDA-approved by the end of November and broadly distributed by the middle of 2021," they added.
-
Why emergency COVID-vaccine approvals pose a dilemma for scientists : After a flurry of positive results from clinical trials of COVID-19 v...
-
The Value of a Cure: An Asset Pricing Perspective : We provide an estimate of the value of a cure using the joint behavior of stock prices ...
-
The Tricky Math of COVID-19 Herd Immunity : Herd immunity differs from place to place, and many factors influence how it’s calculated.